Non Alcoholic Steatohepatitis
Conditions
Brief summary
the current study is to evaluate the efficacy and safety of Montelukast in the treatment of patients with non-alcoholic steatohepatitis (NASH).
Detailed description
This is a randomized, prospective placebo-controlled study that will be conducted on 44 patients who fulfill the selection criteria and will be classified randomly into two groups. Group 1 (Control group n= 22): Patients will receive Placebo once daily at bedtime. Group 2 (Treatment group n= 22): Patients will receive Montelukast 10 mg daily at bedtime. The treatment duration will be 12 weeks. Patients will be recruited from National Liver Institute and Fever, Liver and GIT disease Shebin El-Kom hospital, Egypt. All participants will be informed about the nature of the study. The patients will give their informed consent.The study will be approved by Research Ethics Committee of faculty of pharmacy -Tanta University. Data of all patients will be private and confidential. Any unexpected risk will be reported to patients and ethical committee on time
Interventions
OTHERPlacebo
Placebo tabled every day
DRUGMontelukast
Montelukast 10 mg daily at bed time.
Sponsors
Tanta University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Intervention model description
randomized, prospective placebo controlled study that will be conducted on 44 patients who fulfill the selection criteria and will be classified randomly into two groups. Group 1 (Control group n= 22): Patients will receive Placebo once daily at bedtime. Group 2 (Treatment group n= 22): Patients will receive Montelukast 10 mg daily at bedtime. The treatment duration will be 12 weeks.
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Adult (\>18 years) overweight/obese subjects who have persistently abnormal aminotransferase level in two separate occasions over the past six months. NAFLD will be assumed in patients with moderately elevated aminotransferase activities (\<3x the upper limit of normal). There is evidence of hepatic steatosis by imaging (increased liver echogenicity (bright), stronger echoes in the hepatic parenchyma, vessel blurring, and narrowing of the lumen of the hepatic veins) and there is no cause for secondary hepatic fat accumulation such as significant alcohol consumption, use of steatogenic medication or hereditary disorders. Patients with fibroscan score \>7 kPa and \<14 kPa will be included in the study.
Exclusion criteria
* Alcohol abusers. * Presence of evidence for viral or autoimmune hepatitis. * Diabetic patients. * Patients with Wilson's disease and patients with hemochromatosis. * Patients with decompensated liver disease. * Patients show hypersensitivity to studied medications. * Patients taking medication known to cause steatosis. * Patients with other comorbid conditions that could potentially elevate transaminase, such as congestive heart failure, malignancy. * Pregnancy and lactating women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| serum 8-Hydroxy2-deoxyguanisine (8-OHdG) | 12 Weeks | Quantitative detection of human 8-OHdG will be done using commercially available Enzyme-linked Immunosorbent assay kits. |
| TNF-α. | 12 Weeks | Quantitative detection of TNF-α will be done using commercially available Enzyme-linked Immunosorbent assay kits. |
| Alanine aminotransferase (ALT). | 12 Weeks | ALT will be measured by colorimetric method. |
| Aspartate aminotransferase (AST) | 12 Weeks | AST will be measured by colorimetric method. |
| ɤ-glutamyltranspeptidase(GGT) | 12 Weeks | ɤ-glutamyltranspeptidase(GGT) will be measured by colorimetric method. |
Countries
Egypt
Outcome results
None listed